Post by Michael Green

Professor and Vice Chair for Research, Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center

πŸ“„Sneak peek at new work from Haopeng Yang, in collaboration with the labs of Nathanael Gray and Gerald Crabtree. BCL6 TCIPs are highly effective in high-risk models of DLBCL with strong BCL6 expression, including post-CAR T relapse models. But what happens when tumors have mixed patterns of BCL6 expression? Spoiler alert: π‘·π’π’‚π’”π’•π’Šπ’„π’Šπ’•π’š. DLBCLs represent heterogeneous populations of cells with plasticity to move between phenotypes. Under pressure from BCL6-targeting TCIPs, they polarize to an insensitive BCL6-negative phenotype. But this comes along with other targetable dependencies! We hope you enjoy the read. https://lnkd.in/eXZSHNMs